Targeting DNA Homologous Repair Proficiency With Concomitant Topoisomerase II and c-Abl Inhibition
Critical DNA repair pathways become deranged during cancer development. This vulnerability may be exploited with DNA-targeting chemotherapy. Topoisomerase II inhibitors induce double-strand breaks which, if not repaired, are detrimental to the cell. This repair process requires high-fidelity functio...
Main Authors: | Arafat Siddiqui, Manuela Tumiati, Alia Joko, Jouko Sandholm, Pia Roering, Sofia Aakko, Reetta Vainionpää, Katja Kaipio, Kaisa Huhtinen, Liisa Kauppi, Johanna Tuomela, Sakari Hietanen |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-09-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2021.733700/full |
Similar Items
-
The HSP90 inhibitor KW-2478 depletes the malignancy of BCR/ABL and overcomes the imatinib-resistance caused by BCR/ABL amplification
by: Dachuan Zeng, et al.
Published: (2022-05-01) -
A Small Molecule Inhibitor, OGP46, Is Effective against Imatinib-Resistant BCR-ABL Mutations via the BCR-ABL/JAK-STAT Pathway
by: Liuya Wei, et al.
Published: (2020-09-01) -
BCR-ABL gene amplification in patients with chronic myeloid leukemia and imatinib resistance
by: S. I. Kutzev, et al.
Published: (2022-11-01) -
Novel lncRNA-IUR suppresses Bcr-Abl-induced tumorigenesis through regulation of STAT5-CD71 pathway
by: Xuefei Wang, et al.
Published: (2019-04-01) -
De novo acute megakaryoblastic leukemia with p210 BCR/ABL and t(1;16) translocation but not t(9;22) Ph chromosome
by: Min Xiao, et al.
Published: (2011-11-01)